Whether wavelength for yellow or green laser is chosen for treatment of diabetic macular edema, little clinical difference is seen between the two, according to a review of data.
Differences in visual acuity and OCT parameters for eyes assigned to sham injection plus prompt laser, ranibizumab plus prompt laser and prompt laser-only were analyzed in two randomized clinical trials.
Researchers used green or yellow wavelength at their own discretion.
Eyes in the sham injection plus prompt laser group, receiving green and yellow laser treatment, respectively, had a mean visual acuity letter score of +2.4 and +5.1 at 52 weeks (P = .06) and +2.4 and +6.0 at 104 weeks (P = .13). No differences in OCT thickness were evident.
There were also no meaningful differences in visual acuity and OCT thickness between the ranibizumab plus prompt laser and prompt laser-only groups at 1 and 2 years.
Disclosure: The authors have no relevant financial disclosures.